Log In
Print
BCIQ
Print
Print this Print this
 

MOR202

  Manage Alerts
Collapse Summary General Information
Company MorphoSys AG
DescriptionHuman HuCAL antibody against CD38
Molecular Target CD38
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM)
Regulatory Designation

Partner

Celgene Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today